Posted by Michael Wonder on 16 Aug 2018
Promising more appraisal capacity, NICE revives industry fee idea
10 August 2018 - Rising workload and shrinking budget making charges inevitable.
England’s healthcare cost effectiveness watchdog NICE has returned to its proposal to charge pharma companies for appraisals of drugs – but says smaller companies will have a 25% fee discount.
NICE is proposing that bigger companies pay £126,000 ($160,000) for a single technology appraisal or a highly specialised technology appraisal (for rare disease drugs), or £94,500 for smaller companies.
